Advances in Therapy
Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
Advances in Therapy is of interest to a broad audience of researchers, industry and healthcare professionals, receiving submissions from all over the world, and publishes original research and authoritative reviews focusing on new and existing therapies and interventions, areas of unmet need and general topics of interest to the medical community. Articles published in Advances in Therapy may be accompanied by Plain Language Summaries to assist non-experts (including non-specialists, patients, caregivers and others) in understanding important medical advances.
Moving forward from traditional publishing, Advances in Therapy offers a range of additional features designed to increase visibility and readership. Each paper is accompanied by a bulleted slide summary, giving a time-efficient overview of the content to a wider readership. Articles also have the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are open access and are peer reviewed to the same high standard as the article itself. For questions relating to enhanced features please contact Adisdigitalfeatures@springer.com.
Upon acceptance of your article for publication, you will be required to pay an article processing charge of €580/$660 per typeset page. Additionally, Advances in Therapy offers an open access option for all articles submitted to the journal. If you choose open access publication you will be required to pay an additional fee of €2990/$3760 upon acceptance of your article. The journal will consider fee discounts for developing countries and this is decided on a case by case basis.
Peer Review Process
Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria.
At least two extensive reviews are required to make the editorial decision. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case by case basis and should be sent to the journal editor.
Please note: Advances in Therapy's open access articles are published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0.
For more information about the journal, please contact email@example.com.
Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis
- Journal Title
- Advances in Therapy
- Volume 17 / 2000 - Volume 36 / 2019
- Print ISSN
- Online ISSN
- Springer Healthcare
- Additional Links
- Industry Sectors
To view the rest of this content please follow the download PDF link above.